Exploring systemic erythropoietin in diabetic retinopathy: Longitudinal associations and biomarker potential in the LANDMark cohort

Ingrid A Wise, Siska Dupont Berry, Alisa McKenzie, Jason C Steel, Katie Edwards, Nathan Efron, Christopher J Layton, Charmaine A Ramlogan-Steel · 2026

Read Exploring systemic erythropoietin in diabetic retinopathy: Longitudinal associations and biomarker potential in the LANDMark cohort by Ingrid A Wise, Siska Dupont Berry, Alisa McKenzie, Jason C Steel, Katie Edwards, Nathan Efron, Christopher J Layton, Charmaine A Ramlogan-Steel (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/plos-pone-0358455.txt.

Description

Ingrid A Wise led a team of eight authors studying a hormone and diabetic eye disease, published in PLOS ONE in 2026. Erythropoietin, best known for boosting red blood cells, may also signal damage in diabetic retinopathy, a leading cause of blindness. The team worked within the LANDMark cohort, tracking the hormone over time.

Wise's longitudinal study links levels of the hormone in the body with the course of eye disease, testing its value as a biomarker. A blood test that warns of worsening eye disease could trigger earlier eye checks and treatment. Cohort data gathered over years are precious for this, since eye damage builds slowly. The study adds a candidate signal to a field that needs early warnings.

Catalog record

CREATORIngrid A Wise, Siska Dupont Berry, Alisa McKenzie, Jason C Steel, Katie Edwards, Nathan Efron, Christopher J Layton, Charmaine A Ramlogan-Steel
YEAR2026
COLLECTIONPAPERS
FORMATTXT
FILE SIZE39201
LICENSECC_BY
RIGHTSCC BY
SOURCEPLOS

Source: https://doi.org/10.1371/journal.pone.0358455

Browse the full library · About the Tower of Babel